Project Grant R34DA064618
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Biomotivate LLC a $613,744 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate the PEACE Platform (Personalized Evocative Audiovisual Content for Everyone), a precision medicine tool designed to support emotional regulation and resilience in individuals with opioid use disorders (OUDs). The platform combines generative artificial intelligence, predictive analytics,...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded UCLA a $1.23 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning July 1, 2025, and concluding March 31, 2030. This award supports research investigating the neural circuit mechanisms linking dopaminergic (DA) reward prediction signaling and temporal processing in reinforcement learning. The project will deliver scientific research products through combined experimental and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Massachusetts General Hospital $395,280 under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate AMP-C, a digital therapeutic (DTX) intervention targeting reward dysfunction in individuals with co-occurring Cannabis Use Disorder (CUD) and Major Depressive Disorder (MDD). This five-year project grant, effective July 1, 2025 through June 30, 2030, delivers a user-centered digital...
- Federal Grant Award Summary The University of California, San Francisco received a $1,458,907 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective August 1, 2025, through April 30, 2030. This award supports a longitudinal research initiative examining the pathways between adolescent social media use and substance use (cannabis, nicotine, and alcohol). The project leverages data from the Adolescent Brain...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $7.09M Avenir Award Project Grant to the University of California, Los Angeles (UCLA) under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period July 1, 2025, through June 30, 2029. This research initiative addresses the critical gap between scientific evidence and policy implementation by developing innovative dissemination strategies to increase access to HIV prevention and...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Southern California $750,511 on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot test a brief mobile phone-based intervention targeting prenatal cannabis use. The three-year project, scheduled for completion on March 31, 2029, will deliver a motivational enhancement intervention combining evidence-based harm reduction and cognitive...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, Los Angeles a $315,480 project grant under the Drug Use and Addiction Research Programs (CFDA 93.279) on June 24, 2025, with completion targeted for December 31, 2027. This award supports basic neuroscience research investigating the functions and mechanisms of CRYM-positive astrocytes in the nucleus accumbens (NAC), a brain region critically involved in reward-directed behaviors and...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- Federal Project Grant Award Summary Dartmouth College received a $450,313 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective June 1, 2025, through May 31, 2027. The award funds research investigating the impact of psychotherapeutic advertising claims (PAC) and mental health warning labels on cannabis purchasing behaviors among light-to-moderate cannabis users experiencing depression and/or anxiety symptoms....
- Federal Grant Award Summary The University of California, San Diego received a $158,246 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period July 1, 2025 through June 30, 2027. This award supports research investigating the co-occurrence of posttraumatic stress disorder (PTSD) and substance use disorder (SUD) across developmental stages from childhood through adulthood. The project adopts a developmental...
The National Institute on Drug Abuse (NIDA) awarded UCLA a $188,199 Project Grant effective April 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate a digital therapeutic intervention for individuals with comorbid anxiety disorders and alcohol or cannabis use disorders. The primary deliverable is a mobile application-based intervention titled Anxiety Management Treatment for Substance Use Disorders (AMT/SUD), which adapts evidence-based cognitive behavioral therapy protocols to a digital platform. The development process employs human-centered design methodologies, including focus groups to refine an application prototype, full application development, and a small open trial (N=8) to assess usability and preliminary efficacy of the intervention targeting individuals with mild to moderate cannabis and/or alcohol use disorder. This initiative addresses a critical public health gap by creating the first digital therapeutic specifically designed to simultaneously address the comorbid presentation of anxiety and substance use disorders, conditions that are associated with poor clinical outcomes when treated separately. The award period extends through February 28, 2029, and the research will be conducted at UCLA's Los Angeles, California facility. The project builds upon the principal investigator's established research program in developing integrated cognitive behavioral therapy protocols for this high-risk, underserved population.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $188.2k | 4/16/26 |